TLRY heads into the final stretch before its July earnings with the lending market for its shares near fully exhausted — and options traders suddenly more defensive than they have been in months.
The most striking feature of the current setup is how persistently tight borrow availability has become. Availability has been oscillating between near-zero and single digits for weeks, touching 0% multiple times in May and dipping to 0.56% as recently as June 8. The June 9 reading of 6.7% is the loosest the pool has been in over a week — but that still means fewer than seven shares remain available to borrow for every hundred already out on loan. Cost to borrow has climbed alongside the tightness, running at 10.5% on June 9, up roughly 11% on the week. The ORTEX short score has eased slightly to 72.7 from a peak near 74.4 in late May, but remains firmly elevated, and the utilization rank sits in the bottom 1st percentile of the universe — meaning almost no other stock has less borrow headroom. The picture is one of a deeply committed short base operating with almost no room to add.
Short interest itself tells a slightly less alarming story. It fell nearly 9% on the week to 1.3% of the free float — a low absolute level by any standard — and the direction has been broadly lower since mid-May when it ran closer to 1.7%. That declining trend in share count, set against a borrow market that refuses to loosen, suggests shorts are not building further but are holding existing positions at significant cost. Days to cover from the most recent FINRA settlement is 5.1, which is elevated relative to the stock's size and provides a meaningful friction point for any position exit.
Options positioning added a new wrinkle on June 9. The put/call ratio jumped to 0.25, a reading that in isolation appears mild — but measured against the stock's own 20-day average of 0.19, it is nearly four standard deviations above the norm, the sharpest defensive skew TLRY options have shown in recent weeks. The absolute level remains low compared to the 52-week high of 1.18, so this is not heavy hedging in the traditional sense. But the sudden spike in relative terms on a day the stock recovered 2.8% is worth noting — it suggests some investors are buying downside insurance into the bounce.
The Street picture is dated but directionally consistent with caution. Analyst data runs through early April, so it should be treated as context rather than current guidance. At that point the consensus was a hold, with three buys and six holds and a mean target near $10 — roughly double the current $5.17 price. TD Cowen trimmed its target to $7 from $10 in late March while keeping a buy rating, reflecting slipping conviction. The ORTEX factor scores capture the same tension: EPS momentum over 30 and 90 days ranks in the 99th-100th percentile, which looks bullish, but the EPS surprise rank of just 3 out of 100 suggests the company has consistently underdelivered against in-period estimates even as forward revisions move higher. Value scores look stretched by conventional measures — price-to-book below 0.6 and analyst targets implying roughly 85% upside — but the quality pillar remains weak, with a negative ROA and a low Piotroski F-score.
Among the closest peers, SNDL managed a 1.4% gain on the week while ACB fell 3.1%, tracking TLRY's own decline of roughly 3.9%. CRON was the outlier with a 4% weekly gain. The dispersion across cannabis names reflects the lack of a sector-wide catalyst, with individual moves driven more by idiosyncratic positioning than macro themes.
The next date to watch is July 24, when Tilray reports quarterly results. The borrow availability trend in the days leading into that print — whether it tightens back toward zero or starts to ease — will indicate whether the short base is building conviction ahead of the number or quietly reducing exposure.
See the live data behind this article on ORTEX.
Open TLRY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
